Kronos Bio Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Kronos Bio Inc (KRON) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Kronos Bio Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 9M vs 66,747M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-18.9% annualized vs trailing 12 months), vs decelerating (-88.1%) for its tracked peer group.
- Growth: Kronos Bio Inc generated -26.0% revenue growth year over year in Q1 2025, vs 9.7% for its tracked competitors combined.
- Profitability: Its -448.7% net margin compares with -9.1% for the peer group.
- Peer revenue share: Kronos Bio Inc accounted for 0.1% of combined revenue among its tracked peer group, down from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.12M compares with $0.76M for the peer group (0.2x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
KRON Sales vs. its Competitors, Q1 2025
Kronos Bio Inc reported revenue contraction of 26.03 % year on year in Q1 2025, below its competitors' combined revenue growth of 9.65 %.
With a net margin of -448.71 %, Kronos Bio Inc reported lower profitability than its competitors (-9.07 %).
Kronos Bio Inc generated 0.09 % of the combined sales of its peer group, down from 0.14 % a year earlier.
Kronos Bio Inc vs. its Competitors, Q1 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Kronos Bio Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Kronos Bio Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Kronos Bio Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -26.0% for Kronos Bio Inc. Kronos Bio Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Kronos Bio Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Kronos Bio Inc | No | Yes | Yes | No |
| Competitors combined (22) | ||||
| High-Confidence Competitors (8) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 57.10 % (4 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
KRON Stock Performance relative to its Competitors
KRON Stock Performance relative to High-Confidence Competitors
KRON Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Erasca Inc | 282.9% | Outperformed |
| 2 | Sellas Life Sciences Group Inc | 282.9% | Outperformed |
| 3 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 4 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 5 | Adaptive Biotechnologies Corporation | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Kronos Bio Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Kronos Bio Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Kronos Bio Inc | 53.51 | 9.19 |
| Astrazeneca Plc | 259,526.30 | 58,739.00 |
| Blueprint Medicines Corporation | 8,615.12 | 562.12 |
| Adaptive Biotechnologies Corporation | 4,557.47 | 308.08 |
| Erasca Inc | 4,399.19 | - |
| Relay Therapeutics Inc | 3,588.41 | 0.70 |
| SUBTOTAL | 292,524.65 | 66,814.64 |
Sign in to see all competitors of Kronos Bio Inc .
Sources: Kronos Bio Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Kronos Bio Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Kronos Bio Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| SELLAS Life Sciences Group | Named by the company | 85% |
| AstraZeneca | Named by the company | 85% |
| Prelude Therapeutics | Named by the company | 85% |
| Vincerx Pharma, Inc. | Named by the company | 85% |
| Cyclacel Pharmaceuticals | Named by the company | 85% |
| MEI Pharma | Named by the company | 85% |
| Hutchison Medipharma Ltd. | Named by the company | 85% |
| Pathos | Named by the company | 85% |
| Tolremo | Named by the company | 85% |
| Epigenetix | Named by the company | 85% |
| Merck & Co. | Named by the company | 85% |
| Sumitomo Pharma Oncology | Named by the company | 85% |
| CellCentric | Named by the company | 85% |
| Jazz Pharmaceuticals | Named by the company | 85% |
| Genfleet Therapeutics | Named by the company | 85% |
| National Cancer Institute | Named by the company | 85% |
| Tolero Pharmaceuticals | Named by the company | 85% |
| Lite Strategy Inc | Named by the company | 85% |
| Kb Home | Named by the company | 85% |
| Novabridge Biosciences | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Kronos Bio Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Kronos Bio Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Adaptive Biotechnologies Corporation | Mrd Business Segment 92.47 % |
| Rigel Pharmaceuticals Inc | One Operating 100.00 % |
| Array Technologies Inc | Legacy Operations 97.48 % |
| Novabridge Biosciences | Oncology 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Kronos Bio Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Kronos Bio Inc | 54 | 124,216 | -871,419 |
| Astrazeneca Plc | 259,526 | 706,847 | 123,141 |
| Blueprint Medicines Corporation | 8,615 | 965,844 | -267,576 |
| Adaptive Biotechnologies Corporation | 4,557 | 493,720 | -102,548 |
| Erasca Inc | 4,399 | - | -2,788,573 |
| Relay Therapeutics Inc | 3,588 | 3,620 | -1,489,776 |
| PEERS TOTAL | 292,471 | 762,671 | 102,495 |
Kronos Bio Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Kronos Bio Inc's industry classification, broader than the peer set above. Market cap in millions of $.Kronos Bio Inc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Kronos Bio Inc | 54 | 0.00 % |
Market cap and industry share for the rest of Kronos Bio Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2025-06-20.
Kronos Bio Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 100.00 % | 64.89 % (avg) | +35.1 pp |
| Operating Margin | -765.18 % | industry median | -694.3 pp |
| EBITDA Margin | -685.64 % | -7.21 % (avg) | -678.4 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Kronos Bio Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.6x | 4.5x | -3.9x |
| Return on Equity | -64.22 % | industry aggregate | -79.51 % |
| Return on Invested Capital | -31.49 % | -2.95 % (avg) | -28.54 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Kronos Bio Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | 56.62 % |
| Operating Margin | - | - | -1,937.50 % | -943.21 % |
| Return on Invested Capital | - | -18.03 % | -29.18 % | -36.64 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Kronos Bio Inc's Strategic Group Map
Every company in Kronos Bio Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Kronos Bio Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Kronos Bio Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Kronos Bio Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Kronos Bio Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Kronos Bio Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Kronos Bio Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Kronos Bio Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 694.3 points below the industry median.
- Return on equity 79.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-18.9% annualized vs trailing 12 months).
Opportunities
- A meaningful share of tracked competitors (45.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-88.1% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Kronos Bio Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Kronos Bio Inc | 5.82 | 8.81 | - |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Blueprint Medicines Corporation | 0.36 | 3.16 | 2.48 |
| Adaptive Biotechnologies Corporation | 1.07 | 3.72 | 0.49 |
| Erasca Inc | 4.90 | 9.52 | - |
| Relay Therapeutics Inc | 3.61 | 20.10 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Kronos Bio Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Kronos Bio Inc | Q1 2025 | -26.0 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Blueprint Medicines Corporation | Q1 2025 | +55.5 % | -99.4 % |
| Adaptive Biotechnologies Corporation | Q2 2026 | +21.5 % | - |
| Erasca Inc | Q2 2026 | - | - |
| Relay Therapeutics Inc | Q2 2026 | -48.3 % | - |
| PEERS TOTAL | +7.5 % | +40.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Kronos Bio Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Kronos Bio Inc | Q1 2025 | - | - |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Blueprint Medicines Corporation | Q1 2025 | -12.2 % | +65.9 % |
| Adaptive Biotechnologies Corporation | Q2 2026 | +12.0 % | +80.8 % |
| Erasca Inc | Q2 2026 | - | -73.3 % |
| Relay Therapeutics Inc | Q2 2026 | - | - |
Kronos Bio Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Kronos Bio Inc | - | - | - |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Blueprint Medicines Corporation | - | - | - |
| Adaptive Biotechnologies Corporation | - | - | - |
| Erasca Inc | - | - | - |
| Relay Therapeutics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Kronos Bio Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Kronos Bio Inc | - | 5.82 |
| Astrazeneca Plc | 25.38 | 4.42 |
| Blueprint Medicines Corporation | - | 15.33 |
| Adaptive Biotechnologies Corporation | - | 14.79 |
| Erasca Inc | - | - |
| Relay Therapeutics Inc | - | 5,163.18 |
| PEERS AVERAGE | 32.82 | 4.38 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.